ExpreS2ion Biotech Holding AB

EXPRS2 • ST

SEK 1.445-SEK 0.015 (1.03%)

Estimate

EPS

-3.29

Beta

2.171

Growth

Revenue, YoY

-22.07%

Net income, YoY

16.17%

FCF, YoY

-25.28%

About the company

Ticker

EXPRS2

ISIN

SE0008348262

Country

Denmark

Sector (GICS)

Healthcare

ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.

Frequently asked questions

What sector does ExpreS2ion Biotech Holding AB (EXPRS2) operate in?

ExpreS2ion Biotech Holding AB belongs to the Healthcare sector and operates in the Biotechnology industry.

What is ExpreS2ion Biotech Holding AB (EXPRS2) current stock price?

As of the latest data, ExpreS2ion Biotech Holding AB stock price is SEK 1.45, with a previous close of SEK 1.46. ExpreS2ion Biotech Holding AB lost -SEK 0.02 in the last trading session, representing a -1.03% loss.

What is ExpreS2ion Biotech Holding AB (EXPRS2) current market capitalization?

ExpreS2ion Biotech Holding AB market cap is approximately 14.28 million.

What is ExpreS2ion Biotech Holding AB (EXPRS2) Earnings Per Share (EPS)?

The trailing EPS is -SEK 3.29.

What is ExpreS2ion Biotech Holding AB (EXPRS2) EBITDA?

ExpreS2ion Biotech Holding AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.47 million.

Does ExpreS2ion Biotech Holding AB (EXPRS2) pay dividends?

No. ExpreS2ion Biotech Holding AB does not pay a dividend.

When is ExpreS2ion Biotech Holding AB (EXPRS2) next earnings report?

ExpreS2ion Biotech Holding AB is expected to release its next earnings report on June 30, 2026.

What is ExpreS2ion Biotech Holding AB (EXPRS2) beta (volatility) score?

ExpreS2ion Biotech Holding AB has a beta of 2.171, indicating very high volatility compared to the market.